Results 11 to 20 of about 1,044,683 (223)

Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer

Chinese Journal of Lung Cancer, 2017
Background and objective Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions.
Xu LI, Bin AI, Ping ZHANG, Lin LI, Xiaonan WU   +4 more
doaj   +2 more sources

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients [PDF]

Frontiers in Pharmacology, 2018
Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li, Hong Zhang, Xiaoxue Zhu, Chengjiao Liu, Min Wu, Cuiyun Li, Xiaojiao Li, Lei Gao, Yanhua Ding   +8 more
doaj   +2 more sources

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy [PDF]

Case Reports in Urology, 2014
Primary urethral cancer is rare and accounts for only 0.003% of all malignancies arising from the female genitourinary tract. Due to the rarity of this disease, no consensus exists regarding the optimal therapeutic approach.
Yasmin M. Abaza, Carlos Alemany
doaj   +2 more sources

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas [PDF]

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +3 more sources

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System

SAGE Open Medicine, 2019
Objectives: Paclitaxel is a highly effective antitumor agent with notable adverse events, including hypersensitivity reactions, peripheral neuropathy, arthralgia, myalgias, and neutropenia.
Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna Hatahira, Yumi Motooka, Satoshi Nakao, Ririka Mukai, Kouseki Hirade, Tomoaki Yoshimura, Takeshi Kato, Hirofumi Takeuchi, Mitsuhiro Nakamura   +13 more
doaj   +2 more sources

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma

Translational Oncology, 2018
Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is
Md Sazzad Hassan, Niranjan Awasthi, Jun Li, Fiona Williams, Margaret A. Schwarz, Roderich E. Schwarz, Urs von Holzen   +6 more
doaj   +2 more sources

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

Drug Design, Development and Therapy, 2015
Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy.
Kundranda,Madappa N, Niu,Jiaxin
openaire   +5 more sources

Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice [PDF]

Безопасность и риск фармакотерапии, 2022
Paclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug.
R. N. Alyautdin, B. K. Romanov, В. К. Лепахин, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov   +5 more
doaj   +1 more source

A retrospect study based on real-world data to observe metabolic function in cancer patients using albumin-bound paclitaxel

Scientific Reports, 2023
There is substantial evidence that albumin-bound paclitaxel (nab-paclitaxel) is effective and safe for the treatment of breast, lung and pancreatic cancers.
Qi Zheng, Hanzhou Wang, Chao Xue, Shuhan Yang, Yan Wang, Wei Hou, Ying Zhang   +6 more
doaj   +2 more sources

A case report of hypocalcemia after chemotherapy with albumin‐bound paclitaxel

Precision Medical Sciences, 2023
Hypocalcemia is a fatal electrolytic disorder defined as corrected serum total calcium levels
Zhongchao Wang, Huanfeng Zhu, Jing Wu, Mingyu Du, Wenjie Guo, Zhaoxia Dai   +5 more
doaj   +2 more sources